134526-69-5

Basic information

• Product Name: (R)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: (R)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;2R-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-PIPERIDINECARBOXYLIC ACID, 2-FORMYL-, 1,1-DIMETHYLETHYL ESTER, (R);(R)-1-Boc-2-piperidinecarboxaldehyde;(R)-2-Formyl-1-piperidinecarboxylic acid tert-butyl ester;1-Piperidinecarboxylic acid, 2-formyl-, 1,1-dimethylethyl ester, (2R)-;tert-butyl (2R)-2-forMylpiperidine-1-carboxylate;tert-Butyl (3R)-3-formylmorpholine-4-carboxylate
• CAS NO: 134526-69-5
• Molecular Formula: C₁₁H₁₉NO₃
• Molecular Weight: 213.27
• Mol File: 134526-69-5.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 295.431 °C at 760 mmHg
• Flash Point: 132.472 °C
• Appearance: /
• Density: 1.115 g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.519
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (R)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(134526-69-5)
• EPA Substance Registry System: (R)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(134526-69-5)

Safety Data

• Hazardous Substances Data: 134526-69-5(Hazardous Substances Data)

Usage

General Description

(R)-2-formyl-piperidine-1-carboxylic acid tert-butyl ester is a chemical compound with the molecular formula C12H21NO3. It is a derivative of piperidine and contains a formyl group as well as a tert-butyl ester functional group. (R)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is commonly used in the field of organic chemistry as a building block for the synthesis of various pharmaceuticals and other complex organic molecules. It is also used as a reagent in chemical research and development. The tert-butyl ester group increases the compound's stability and makes it easier to handle in laboratory settings.

InChI:InChI=1/C11H19NO3/c1-11(2,3)15-10(14)12-7-5-4-6-9(12)8-13/h8-9H,4-7H2,1-3H3

Upstream product

• 203056-15-9 tert-butyl (2R)-2-[methoxy(methyl)carbamoyl]piperidine-1-carboxylate 
• 35677-83-9 (+)-2R-Piperidine-2-carboxylic acid methyl ester 
• 1013212-42-4 tert-butyl 1-(R)-2-((S)-1,2-dihydroxylethyl)piperidine-1-carboxylate 
• 1268624-35-6 (R)-tert-butyl 2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)piperidine-1-carboxylate 
• 1268624-34-5 (R)-tert-butyl 6-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-5,6-dihydropyridine-1(2H)-carboxylate 
• 1073314-61-0 tert-butyl N-allyl-N-(1R)-1-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-3-butenylcarbamate 
• 75844-69-8 t-butyl piperidinecarboxylate 
• 68-12-2 N,N-dimethyl-formamide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1723-00-8 (R)-(+)-pipecolic acid 
• 3197-44-2 (2R)-piperidin-2-ylmethanol 
• 28697-17-8 N-BOC-D-pipecolic acid 
• 164456-75-1 1-(R)-tert-butyl 2-methyl piperidine-1,2-dicarboxylate 
• 134441-61-5 tert-butyl (2R)-2-(hydroxymethyl)piperidine-1-carboxylate 

Downstream Products

• 125279-72-3 (1R,2R,8aR)-lentiginosine 
• 160169-49-3 (1R,2S,8aR)-1,2-dihydroxy-hexahydroindolizin-3(5H)-one 
• 134441-61-5 tert-butyl (2R)-2-(hydroxymethyl)piperidine-1-carboxylate 
• 1094503-62-4 tert-butyl (2R)-2-[(R)-(3-chloro-5-fluorophenyl)(hydroxy)methyl]piperidine-1-carboxylate 
• 1094503-59-9 tert-butyl (2R)-2-[(S)-(3-chloro-5-fluorophenyl)(hydroxy)methyl]piperidine-1-carboxylate 
• 138775-33-4 Fmoc-D-Phe-L-Ile-D-Pip-L-Pip-D-(N-allyl)Phe-L-Pro-OCH₂Ph 
• 144073-33-6 Fmoc-L-Ile-D-Pip-L-Pip-D-(N-allyl)Phe-L-Pro-OCH₂Ph 
• 1026159-93-2 D-Pip-L-Pip-D-(N-allyl)Phe-L-Pro-OCH₂Ph 
• 220384-49-6 (2R)-2-vinylpiperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson’s disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to23, which manifested IC50values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.23showed efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-PD medicine. Further studies revealed that different from Madopar,23likely has specific anti-PD mechanisms involving lowering IDO1 expression, alleviating dopaminergic neurodegeneration, reducing inflammatory cytokines and quinolinic acid in mouse brain, and increasing kynurenic acid in mouse blood.

Benzimidazole-2-piperazine compound, its pharmaceutical composition and its preparation and use

The invention relates to a benzimidazole-2-piperazine derivative and a preparing method and application of the benzimidazole-2-piperazine derivative in medicine, in particular to a novel benzimidazole-2-piperazine derivative shown in the general formula (I), a preparing method of the derivative, a pharmaceutical composition containing the derivative and application of the derivative serving as a therapeutic agent, especially serving as a poly (ADP-ribose) polymerase (PARP) inhibitor. In the general formula (I), R refers to hydrogen or halogen, G refers to carbonyl or methylene, m is 1-2, n is 1-3, and Q refers to hydrogen or C1-C4 alkyl. When X is methylene and Y is NR1 or methylene, X is NR1; R1 refers to hydrogen, C1-C6 alkyl, benzyl, COR2 or SO2R2; R2 refers to the following groups which are not substituted or groups substituted by 1-3 substituent groups, including C1-C6 alkyl, C3-C8 naphthenic base, phenyl, benzyl, naphthyl and C5-C10 aromatic heterocycle base, heterocycle in the C5-C10 aromatic heterocycle base comprises 1-3 heteroatoms selected from N, O and S, and the substituent groups are selected from the following atoms or groups of C1-C6 alkyl, C1-C6 alkoxy, halogen, amidogen, nitryl, sulfydryl, hydroxyl, cyanogroup and trifluoromethyl. The general formula (I) is shown in the specification.

SUBSTITUTED ADIPIC ACID AMIDES AND USES THEREOF

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein A is a five to eight membered monocyclic or a nine to twelve membered bicyclic heterocyclic ring, as further defined herein; Y is S, CH2, or CH; Z is CH or N; R7 and R9 are hydrogen or (C1-C6)alkyl; R2 is (C1 C6)alkoxy, OH, CN, (C1-C6)alkyl, halogen, or CF3; r and s are 0, 1, or 2; and R1 and R3 are as further defined herein. These compounds are agonists, partial agonists and/or modulators of the NPY4 receptor and may be used for the treatment and prophylaxis of obesity, food intake, and other diseases and conditions modulated by the NPY4 receptor.